Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

References

• Herrera GA, Turbat-Herrera EA. Renal diseases with organized deposits: an algorithmic approach to classification and clinicopathologic diagnosis. Arch Pathol Lab Med 2010;134:512–531.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751–3757.
   PubMed Web of Science ®Google Scholar
• Mhaskar R, Kumar A, Behera M, Kharfan-Dabaja MA, Djulbegovic B. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant 2009;15:893–902.
   PubMed Web of Science ®Google Scholar
• Comenzo RL. Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma 2006;7:182–185.
   PubMedGoogle Scholar
• Gertz MA, Comenzo R, Falk RH, Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–328.
   PubMed Web of Science ®Google Scholar
• Connors LH, Prokaeva T, Lim A, Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 2009;158:607–614.
   PubMed Web of Science ®Google Scholar
• Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957–4959.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Ansell SM, Dingli D, Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 2008;83:1131–1138.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Kumar SK, Lacy MQ, Comparison of high-dose CY and growth factor with growth factor alone for mobili zation of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009;43:619–625.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant 2007;40:989–993.
   PubMed Web of Science ®Google Scholar
• Palladini G, Campana C, Klersy C, Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440–2445.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR. Amyloidosis. Best Pract Res Clin Haematol 2005;18:709–727.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025–1031.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Katzmann JA, Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378–3383.
   PubMed Web of Science ®Google Scholar
• Morris KL, Tate JR, Gill D, Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Intern Med J 2007;37:456–463.
   PubMed Web of Science ®Google Scholar
• Jones NF, Hilton PJ, Tighe JR, Hobbs JR. Treatment of “primary” renal amyloidosis with melphalan. Lancet 1972;2:616–619.
   PubMed Web of Science ®Google Scholar
• Skinner M, Anderson J, Simms R, Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290–298.
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin DC, High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85–93.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Moreau P, Leblond V, et al.; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.N Engl J Med 2007;357:1083–1093.
   PubMed Web of Science ®Google Scholar
• Mehta J, Dispenzieri A, Gertz MA. High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis. Biol Blood Marrow Transplant 2010;16:138–140.
   PubMed Web of Science ®Google Scholar
• Girnius S, Seldin DC, Skinner M, Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis. Ann Hematol 2010;89:579–584.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 2007;92:1415–1418.
   PubMed Web of Science ®Google Scholar
• Yagi S, Akaike M, Ozaki S, Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis. Intern Med 2007;46:1705–1710.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, Litzow MR, Gertz MA. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001;28:381–385.
   PubMed Web of Science ®Google Scholar
• Schuh A, Dandridge J, Haydon P, Littlewood TJ. Encephalopathy complicating high-dose melphalan. Bone Marrow Transplant 1999;24:1141–1143.
   PubMed Web of Science ®Google Scholar